Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 5, 2009, Pages 2120-2128

  Smee, Donald F ^a   Hurst, Brett L ^a   Wong, Min Hui ^a   Bailey, Kevin W ^a   Morrey, John D ^a  

^a UTAH STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; AMANTADINE; OSELTAMIVIR; PLACEBO; RIBAVIRIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; CELL CULTURE; CELL STRAIN; CONTROLLED STUDY; DISEASE SEVERITY; DRUG POTENTIATION; INFLUENZA; INFLUENZA VIRUS A H5N1; MONOTHERAPY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS STRAIN; WILD TYPE;

AMANTADINE; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; RIBAVIRIN; SPECIFIC PATHOGEN-FREE ORGANISMS; TREATMENT OUTCOME;

EID: 66149113991     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01012-08     Document Type: Article

References (29)

1. Abed, Y., N. Goyette, and G. Boivin. 2005. Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations. Antimicrob. Agents Chemother. 49:556-559. (Pubitemid 40175661)
2. Centers for Disease Control and Prevention. 2008. Interim within-season estimate of the effectiveness of trivalent inactivated influenza vaccine - Marshfield, Wisconsin, 2007-08 influenza season. MMWR Morb. Mortal. Wkly. Rep. 57:393-398.
3. Cheung, C. L., J. M. Rayner, G. J. Smith, P. Wang, T. S. Naipospos, J. Zhang, K. Y. Yuen, R. G. Webster, J. S. Peiris, Y. Guan, and H. Chen. 2006. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J. Infect. Dis. 193:1626-1629. (Pubitemid 43839465)
4. Crusat, M., and M. D. de Jong. 2007. Neuraminidase inhibitors and their role in avian and pandemic influenza. Antivir. Ther. 12:593-602. (Pubitemid 47235502)
5. de Jong, M. D., T. T. Tran, H. K. Truong, M. H. Vo, G. J. Smith, V. C. Nguyen, V. C. Bach, T. Q. Phan, Q. H. Do, Y. Guan, J. S. Peiris, T. H. Tran, and J. Farrar. 2005. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353:2667-2672. (Pubitemid 41817715)
6. Deyde, V. M., X. Xu, R. A. Bright, M. Shaw, C. B. Smith, Y. Zhang, Y. Shu, L. V. Gubareva. N. J. Cox, and A. I. Klimov. 2007. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J. Infect. Dis. 196:249-257. (Pubitemid 47047464)
7. Eriksson, B., E. Helgstrand, N. G. Johansson, A. Larsson, A. Misiorny, J. O. Norén, L. Philipson, K. Stenberg, G. Stening, S. Stridh, and B. Oberg. 1977. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob. Agents Chemother. 11:946-951. (Pubitemid 8129651)
8. Fereidouni, S. R., T. C. Harder, and E. Starick. 2008. Rapid pathotyping of recent H5N1 highly pathogenic avian influenza viruses and of H5 viruses with low pathogenicity by RT-PCR and restriction enzyme cleavage pattern (RECP). J. Virol. Methods 154:14-19.
9. Galabov, A. S., L. Simeonova, and G. Gegova. 2006. Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type 1 (H3N2) influenza virus in mice. Antivir. Chem. Chemother. 17:251-258.
10. Govorkova, E. A., H. B. Fang, M. Tan, and R. G. Webster. 2004. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic antiinfluenza virus effects in MDCK cells. Antimicrob. Agents Chemother. 48:4855-4863. (Pubitemid 39577694)
11. Hata, M., M. Tsuzuki, Y. Goto, N. Kumagai, M. Harada, M. Hashimoto, S. Tanaka, K. Sakae, T. Kimura, H. Minagawa, and Y. Miyazaki. 2007. High frequency of amantadine-resistant influenza A (H3N2) viruses in the 2005-2006 season and rapid detection of amantadine-resistant influenza A (H3N2) viruses by MAMA-PCR. Jpn. J. Infect. Dis. 60:202-204. (Pubitemid 47365041)
12. Hay, A. J., A. J. Wolstenholme, J. J. Skehel, and M. H. Smith. 1985. The molecular basis of the specific anti-influenza action of amantadine. EMBO J. 4:3021-3024.
13. Hayden, F. G., R. G. Douglas, Jr., and R. Simons. 1980. Enhancement of activity against influenza viruses by combinations of antiviral agents. Antimicrob. Agents Chemother. 18:536-541. (Pubitemid 11224626)
14. Ilyushina, N. A., N. V. Bovin, R. G. Webster, and E. A. Govorkova. 2006. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antivir. Res. 70:121-131. (Pubitemid 43765615)
15. Ilyushina, N. A., E. A. Govorkova, and R. G. Webster. 2005. Detection of amantadine-resistant variants among avian influenza viruses isolated in North America and Asia. Virology 341:102-106. (Pubitemid 41356578)
16. Ilyushina, N. A., A. Hay, N. Yilmaz, A. C. M. Boon, R. G. Webster, and E. A. Govorkova. 2008. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob. Agents Chemother. 52:3889-3897.
17. Ilyushina, N. A., E. Hoffmann, R. Salomon, R. G. Webster, and E. A. Govorkova. 2007. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antiviral Ther. 12:363-370. (Pubitemid 46787981)
18. Komar, N., and B. Olsen. 2008. Avian influenza virus (H5N1) mortality surveillance. Emerg. Infect. Dis. 14:1176-1178.
19. Le, Q. M., M. Kiso, K. Someya, Y. T. Sakai, T. H. Nguyen, K. H. Nguyen, N. D. Pham, H. H. Nguyen, S. Yamada, Y. Muramoto, T. Horimoto, A. Takada, H. Goto, T. Suzuki, Y. Suzuki, and Y. Kawaoka. 2005. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437:1108. (Pubitemid 41509341)
20. Leneva, I. A., N. Roberts, E. A. Govorkova, O. G. Goloubeva, and R. G. Webster. 2000. The neuraminidase inhibitor GS4104 (oseltamivir phos- phate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza virus. Antivir. Res. 48:101-115.
21. Madren, L. K., C. Shipman, and F. G. Hayden. 1995. In vitro inhibitory effects of combinations of anti-influenza agents. Antivir. Chem. Chemother. 6:109-113.
22. Masihi, K. N., B. Schweiger, T. Finsterbusch, and H. Hengel. 2007. Low dose oral combination chemoprophylaxis with oseltamivir and amantadine for influenza A virus infections in mice. J. Chemother. 19:295-303. (Pubitemid 47075125)
23. Prichard, M. N., and C. Shipman, Jr. 1990. A three dimensional model to analyze drug-drug interactions. Antivir. Res. 14:181-206.
24. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
25. Sidwell, R. W., D. L. Barnard, C. W. Day, D. F. Smee, K. W. Bailey, M.-H. Wong, J. D. Morrey, and Y. Furuta. 2007. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob. Agents Chemother. 51:845-851. (Pubitemid 46355265)
26. Smee, D. F., K. W. Bailey, A. C. Morrison, and R. W. Sidwell. 2002. Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin. Chemotherapy 48:88-93. (Pubitemid 34507601)
27. Smee, D. F., J. H. Huffman, A. C. Morrison, D. L. Barnard, and R. W. Sidwell. 2001. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activity. Antimicrob. Agents Chemother. 45:743-748. (Pubitemid 32182019)
28. Smee, D. F., M.-H. Wong, K. W. Bailey, and R. W. Sidwell. 2006. Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses. Antivir. Chem. Chemother. 17:185-192. (Pubitemid 46395546)
29. Webster, R. G., and E. A. Govorkova. 2006. H5N1 influenza - continuing evolution and spread. N. Engl. J. Med. 355:2174-2177.